Eng

H2, Inc. Secures $16 Million in Bridge Funding to Expand Flow Battery Manufacturing Capacity

PR Newswire (美通社)
更新於 01月22日00:10 • 發布於 01月21日23:51 • PR Newswire

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- H2, Inc., an industry-leading vanadium flow battery (VFB) developer and manufacturer headquartered in South Korea, successfully raised $16 million in recent bridge funding, finalized in the second half of 2024. This brings the company's total accumulated funding to $77 million. The round was led by STIC Investments which is one of the largest and a leading private equity firm in Korea, with participation from KRUN Ventures and Lighthouse Combined Investment.

The newly raised capital will be primarily allocated to constructing the company's new, state-of-the-art K2 Plant. This facility will significantly expand H2's manufacturing capacity to 1.2 GWh per annum, marking a major milestone in the global flow battery and long-duration energy storage industry. Scheduled to begin operations in 2026, the K2 Plant will triple the current capacity of the K1 Plant, which stands at 330 MWh per year. The company has already secured the land for the K2 Plant to achieve its target annual production capacity as quickly as possible.

The K2 Plant will focus on producing H2's three flagship VFB products: the EnerFLOWTM 500 series, optimized for 4-hour energy storage applications, and the EnerFLOWTM 600 series, engineered for applications lasting 8 hours or more. The EnerFLOW 600 series incorporates H2's proprietary HYPERSTRUCTURETM technology, which significantly reduces system footprint. The first EnerFLOWTM 640 units are scheduled to be deployed in Spain's largest 8.8 MWh VFB project, with installation planned for mid-2025. In addition to the EnerFLOWTM series, the plant will support the mass production of UL-certified, high-performance 5000-series VFB stacks based on H2's proprietary design. These stacks are a key factor for success in the VFB industry.

廣告(請繼續閱讀本文)

Dr. Shin Han, founder and CEO of H2, Inc. stated, "The successful bridge funding strongly validates H2's commercial readiness in terms of product quality and mass production capability. The forthcoming K2 Plant will be a pivotal asset, enabling us to meet the growing global demand for sustainable long-duration energy storage solutions that enhance grid resilience and support renewable energy adoption"

查看原始文章

更多 Eng 相關文章

China's first AI-powered self-healing power grid system successfully tested
XINHUA
Xinhua Commentary: China's democracy serves the people, safeguards development
XINHUA
Vlog | Dialogue with NPC deputy: advocating rural education in deep mountains
XINHUA
Xinhua News | UK PM announces new 1.6-bln-pound deal for Ukraine to buy missiles
XINHUA
Oscars 2025: Asian designers behind stunning celebrity red carpet looks
Tatler Hong Kong
HONOR Announces 7 Years of Android OS and Security Updates for the HONOR Magic Series
PR Newswire (美通社)
Brunei records highest economic growth rate since 1999
XINHUA
Addentax Group Corp. Regains Compliance with Nasdaq's Minimum Bid Price Requirement
PR Newswire (美通社)
CBAK Energy to Participate at Upcoming Jefferies 6th Asia Forum in Hong Kong
PR Newswire (美通社)
HONOR Introduced Four AI Technologies at MWC 2025
PR Newswire (美通社)
Oscars 2025: A dazzling display of jewellery from Cartier, De Beers, Bulgari and more
Tatler Hong Kong
Exclusive Markets Opens Dubai Rep. Office and Launches a Special Ramadan Promotion
PR Newswire (美通社)
Fushi Deepens Its Reach across Southeast Asia, Leveraging AI to Drive SaaS Innovation
PR Newswire (美通社)
SunCar Partners with Visa to Empower ICBC Cardholder Benefits in China's Affluent Consumer Market
PR Newswire (美通社)
Milan Fashion Week: Giuseppe Zanotti teases Anson Lo collab for fall-winter 2025 collection
Tatler Hong Kong
Interview: CBA All-Star Weekend honors past while fueling China's basketball future
XINHUA
Edward Lee on ‘Culinary Class Wars’, his struggle with identity and the future of innovation
Tatler Hong Kong
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
PR Newswire (美通社)
Meizu Launch Overseas Flyme AI Ecosystem Strategy
PR Newswire (美通社)
3 mainland university students honored for courage, heroism in Hong Kong
XINHUA
Xinhua Headlines: Europe unveils plan for Ukraine peace deal amid Transatlantic rifts
XINHUA
HONOR Underscores Commitment to Open Collaboration at MWC Barcelona 2025
PR Newswire (美通社)